Therapeutic Response

MET Exon 14 (Deletion) status confers therapeutic sensitivity to Tepotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tepmetko (tepotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Tepmetko (tepotinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.